Charlotte's DeFloria talks U.S. pot reclassification

Executive Summary

• DeFloria Inc. (a subsidiary of Charlotte's Web Holdings Inc.) views the Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III as a critical validation of its strategy and a major accelerator for its pharmaceutical cannabinoid drug development.
• DeFloria is currently advancing AJA001, a cannabinoid-based investigational new drug (IND) for autism-related irritability, through the FDA’s botanical drug pathway.
• The company has achieved significant regulatory milestones, including a cleared botanical IND application, completion of a Phase 1 trial demonstrating safety, and FDA authorization to initiate a Phase 2 clinical program.

Key Details

• Regulatory Context: The release cites a Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III, which DeFloria claims validates the therapeutic value of cannabinoids and reduces compliance risks for pharmaceutical partnerships.
• Drug Candidate: AJA001 oral solution, a botanical cannabinoid formulation targeting irritability associated with autism spectrum disorder.
• Clinical Milestones:
  • Cleared botanical IND application.
  • Received study-may-proceed letter from the FDA.
  • Completed Phase 1 PK/PD clinical trial, demonstrating safety and a well-tolerated dosing profile.
  • Received FDA authorization to initiate a Phase 2 clinical program.
• Strategic Positioning: DeFloria is positioned to leverage the rescheduling for expanded federal research financing, increased collaboration with medical institutions, and greater institutional investment due to decreased regulatory and compliance risk.
• Partnerships: DeFloria was formed in 2023 by AJNA BioSciences PBC and Charlotte's Web Holdings, with a subsidiary of British American Tobacco PLC as the lead investor.

Notable Quotes

• "Charlotte's Web ignited the era of cannabinoid medicine, and DeFloria is the next chapter, elevating that mission with scientific rigour and FDA pathways... Federal policy is finally catching up to what patients, academics and clinicians have long understood: cannabinoids hold real therapeutic power." — Joel Stanley, Co-founder of Charlotte's Web and Chair of the DeFloria Board.
• "This policy shift opens the door to an entirely new level of potential investment, partnership and scientific collaboration... DeFloria is initiating the phase 2 clinical program at exactly the right moment -- as federal recognition of cannabinoid medicine can unlock capital inflows and strategic interest across the biopharmaceutical industry." — Jared Stanley, CEO of DeFloria.